Publications

Department of Medicine faculty members published more than 3,000 peer-reviewed articles in 2022.

Journal of the National Cancer Institute

Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

2022

Authors: Rodriguez CP, Kang H, Geiger JL, Burtness B, Chung CH, Pickering CR, Fakhry C, Le QT, Yom SS, Galloway TJ, Golemis E, Li A, Shoop J, Wong S, Mehra R, Skinner H, Saba NF, Flores ER, Myers JN, Ford JM, Karchin R, Ferris RL, Kunos C, Lynn JM, Malik S

Kidney Medicine

Estimated Kidney Tubular Secretion and Kidney, Cardiovascular, and Mortality Outcomes in CKD: The Systolic Blood Pressure Intervention Trial (SPRINT).

2022

Authors: Simon B. Ascher, Michael G. Shlipak, Ronit Katz, Alexander L. Bullen, Rebecca Scherzer, Stein I. Hallan, Alfred K. Cheung, Kalani L. Raphael, Michelle M. Estrella, Vasantha K. Jotwani, Jesse C. Seegmiller, Joachim H. Ix, Pranav S. Garimella

Clinical Cancer Research

Abstract PR01: Computational identification of targetable dependencies in hepatocellular carcinoma (HCC) associated with hepatitis B virus (HBV) replication.

2022

Authors: Huat Chye Lim, Rigney Turnham, Katherine Lo, Yeonjoo Hwang, John Gordan

Clinical Cancer Research

Abstract PO023: Uncovering hepatitis B virus-induced signaling changes in hepatocellular carcinoma.

2022

Authors: Rigney E Turnham, Huat Chye Lim, Lucille Ferret, Katherine Lo, LeeAnn Wang, Alex Choi, John D Gordan

Clinical Cancer Research

Abstract PO017: HBV alters YAP regulation in liver cancer by remodeling PP2A complexes.

2022

Authors: John Gordan, Adriana Pitea, Rigney E Turnham, Manon Eckhardt, Gwendolyn M Jang, Huat Lim, Alex L Choi, Sourav Bandyopadhyay, Danielle Swaney, Kevan Shokat, Trey Ideker, Nevan Krogan

Annals of Oncology

1751P Impact of squamous histology on clinical outcomes and molecular profiling in metastatic urothelial carcinoma (mUC) patients (pts) treated with newer therapies.

2022

Authors: P.S. Deshmukh, I. De Kouchkovsky, L. Zhang, T. Jindal, K. Reyes, E. Hernandez Romero, E. Chan, A. Desai, H.T. Borno, D. Kwon, A. Wong, R. Bose, R. Aggarwal, S. Porten, L. Fong, E.J. Small, J. Chou, T. Friedlander, V.S. Koshkin

Annals of Oncology

1404P A phase II study of ZEN-3694 (ZEN), enzalutamide (ENZ), and pembrolizumab (P) in metastatic castration resistant prostate cancer (mCRPC): Interim safety results.

2022

Authors: T. Jindal, H. Han, P.S. Deshmukh, I. De Kouchkovsky, D. Kwon, H.T. Borno, V.S. Koshkin, A. Desai, R. Bose, J. Chou, T. Friedlander, E.J. Small, A. Angelidakis, M.S. Johnson, S. Feng, A. Patnaik, L. Fong, J. Alumkal, R. Aggarwal

Annals of Oncology

1379P A phase Ib study of a single priming dose of 177Lu-PSMA-617 coupled with pembrolizumab in metastatic castration resistant prostate cancer (mCRPC).

2022

Authors: R. Aggarwal, L. Trihy, E. Hernandez Romero, S. Luch Sam, M. Rastogi, I. De Kouchkovsky, E.J. Small, F. Feng, D. Kwon, T. Friedlander, H.T. Borno, R. Bose, J. Chou, V.S. Koshkin, A. Desai, S. Feng, A. Angelidakis, M.S. Johnson, L. Fong, T. Hope

Journal for immunotherapy of cancer

Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI.

2022

Authors: Gupta S, Garcia-Carro C, Prosek JM, Glezerman I, Herrmann SM, Garcia P, Abudayyeh A, Lumlertgul N, Malik AB, Loew S, Beckerman P, Renaghan AD, Carlos CA, Rashidi A, Mithani Z, Deshpande P, Rangarajan S, Shah CV, Seigneux S, Campedel L, Kitchlu A, Shin DS, Coppock G, Ortiz-Melo DI, Sprangers B, Aggarwal V, Benesova K, Wanchoo R, Murakami N, Cortazar FB, Reynolds KL, Sise ME, Soler MJ, Leaf DE, ICPi-AKI Consortium Investigators

Journal of women's health (2002)

Gender Differences in National Institutes of Health Grant Submissions Before and During the COVID-19 Pandemic.

2022

Authors: Roubinov D, Haack LM, Folk JB, Rotenstein L, Accurso EC, Dahiya P, Ponce AN, Nava V, Maldonado Y, Linos E, Mangurian C